Corrigendum: A review: the fate of bacteriocins in the human gastrointestinal tract: Do they cross the gut–blood barrier? (Frontiers in Microbiology (2018) 9 (2297) DOI: 10.3389/fmicb.2018.02297)

8Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the original article, there was an error: Incorrect presentation of bacteriocin classification schemes. A correction has been made to the Introduction, paragraph one: Bacteriocins are ribosomally synthesized peptides with antibacterial activity (Cavera et al., 2015). Bacteriocins can be post-translationally modified (PTM) or non-modified and are grouped into different classes (Cotter et al., 2005; Heng et al., 2006; Arnison et al., 2013; Alvarez-Sieiro et al., 2016). For example, lantibiotics are modified bacteriocins and are grouped in class I, they are membrane-active peptides with thioether-containing amino acids lanthionine and β-methyllanthionine. According to the classification scheme proposed by Heng et al. (2006), class I is subdivided into three types of lantibiotics (types A–C). Linear lantibiotics were classified as type A, globular lantibiotics as type B, and multi-component lantibiotics, requiring two or more modified peptides for bioactivity as type C. Subsequent classification schemes for class I have been updated, including changes to the classification of lantibiotics and inclusion of other PTM bacteriocins (Arnison et al., 2013; Alvarez-Sieiro et al., 2016). An extensive review by Arnison et al. (2013) expanded on the nomenclature and classification of modified bacteriocins with the proposed recommendations changing and expanding on previous classification schemes. For example, lanthipeptides (including lantibiotics) are separated into four classes based on modification machinery and using this classification system for lanthipeptides each class can further be grouped based on amino acid sequences of the modified peptides (Cotter et al., 2005; Arnison et al., 2013; Van Staden, 2015). Additionally, the review by Arnison et al. (2013) also expands on the classification and nomenclature of non-lantibiotic/lanthipeptide modified peptides. As reviewed by Alvarez-Sieiro et al. (2016), the unmodified, membrane active, heat stable bacteriocins are grouped in class II, with four subclasses based on structural differences and their mode of action. Anti-listeria, pediocin-like peptides, are grouped in subclass IIa and bacteriocins that require two or more peptides for activity in subclass IIb. Leaderless bacteriocins, without an N-terminal leader peptide, are grouped in class IIc and unmodified bacteriocins that are not pediocin-like or multi-component bacteriocins are grouped in subclass IId. Large heat liable bacteriocins are grouped in class III, subdivided into IIIa (bacteriolysins) and IIIb (non-lytic proteins). Classification schemes for bacteriocins are constantly evolving to accommodate the increase in complexity and diversity of these peptides. Furthermore, with increased understanding of how bacteriocins function and identification of novel bacteriocins the systems in place to group them will need to adapt and change accordingly. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Cite

CITATION STYLE

APA

Dicks, L. M. T., Dreyer, L., Smith, C., & van Staden, A. D. (2018, November 30). Corrigendum: A review: the fate of bacteriocins in the human gastrointestinal tract: Do they cross the gut–blood barrier? (Frontiers in Microbiology (2018) 9 (2297) DOI: 10.3389/fmicb.2018.02297). Frontiers in Microbiology. Frontiers Media S.A. https://doi.org/10.3389/fmicb.2018.02938

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free